SERPINA1 and benign prostatic hyperplasia: In contemporary practice, the most prescribed ABs for BPH are α-1A subtype-selective antagonists that have minimal impact on blood pressure.58 We found that increased risks of adverse cardiovascular outcomes were maintained when the exposure was limited to subtype-selective ABs in sensitivity analyses.